Compare Core Scientific Inc (CORZ) vs TG Therapeutics Inc (TGTX) Price & Performance

Core Scientific (CORZ) trades at $15.41, down 3.32% today, with bearish technical signals and significant fundamental challenges. The company reported a net loss of $288.62 million in 2025 with negative profit margins, though revenue grew to $319.02 million. Analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent news highlights the company's pivot toward AI data center operations and insider buying activity.

Despite strong analyst support, CORZ faces substantial execution risks in its AI infrastructure transition amid persistent losses and negative cash flow. The stock's current price near key support levels presents potential upside if the company can achieve profitability, but investors should weigh the high-risk profile against the optimistic Wall Street projections.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.